Founded in 2010 out of the Pasteur Institute, Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancer with its headquarters in Houston, Texas and Research & Innovation center in Paris.
Invectys exploits a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two platforms: 1) HLA-G, a powerful immune checkpoint and a tumor specific antigen; 2) the universal tumor antigen telomerase (TERT) that is critical to uncontrolled cell growth.